Items where authors include "Pope, A."

Article

Barnes, E. orcid.org/0000-0002-0860-0831, Goodyear, C.S. orcid.org/0000-0001-5926-5941, Willicombe, M. orcid.org/0000-0002-6404-0584 et al. (154 more authors) (2023) SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature Medicine. ISSN 1078-8956

Barnes, E. orcid.org/0000-0002-0860-0831, Goodyear, C.S. orcid.org/0000-0001-5926-5941, Willicombe, M. orcid.org/0000-0002-6404-0584 et al. (154 more authors) (2023) SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature Medicine, 29 (7). pp. 1760-1774. ISSN 1078-8956

James, N.D., Ali, A., Pope, A. et al. (5 more authors) (2022) Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer. BJUI Compass, 3 (6). pp. 484-493. ISSN 2688-4526

Gómez-Guijarro, C., Elbaz, D., Xiao, M. et al. (38 more authors) (2022) GOODS-ALMA 2.0 : starbursts in the main sequence reveal compact star formation regulating galaxy evolution prequenching. Astronomy & Astrophysics, 659. A196. ISSN 0004-6361

Gómez-Guijarro, C., Elbaz, D., Xiao, M. et al. (35 more authors) (2022) GOODS-ALMA 2.0 : source catalog, number counts, and prevailing compact sizes in 1.1 mm galaxies. Astronomy & Astrophysics, 658. A43. ISSN 0004-6361

Zhou, L., Elbaz, D., Franco, M. et al. (30 more authors) (2020) GOODS-ALMA: Optically dark ALMA galaxies shed light on a cluster in formation at z = 3.5. Astronomy & Astrophysics, 642. A155. ISSN 0004-6361

Franco, M., Elbaz, D., Bethermin, M. et al. (36 more authors) (2018) GOODS-ALMA: 1.1 mm galaxy survey I. Source catalog and optically dark galaxies. Astronomy and Astrophysics, 620. A152. ISSN 0004-6361

James, N., Pirrie, S., Pope, A. et al. (17 more authors) (2016) TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technology Assessment, 20. 53. ISSN 1366-5278

Andronis, L., Goranitis, I., Pirrie, S. et al. (19 more authors) (2016) Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International. ISSN 1464-4096